Aptevo Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Aptevo Therapeutics Inc. (NASDAQ: APVO) is a clinical-stage biotechnology company focused on developing novel, multispecific immuno-oncology therapeutics designed to harness the human immune system to selectively target and destroy cancer cells. The company's pipeline is built upon its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, which enable the rapid design and engineering of bispecific and trispecific antibody candidates with enhanced specificity, safety profiles, and unique mechanisms of action. Aptevo's lead clinical candidate is mipletamig (a CD123 x CD3 bispecific T-cell engager) currently being evaluated in frontline acute myeloid leukemia (AML). Its second clinical asset, ALG.APV-527, is a tumor-directed 4-1BB agonistic bispecific antibody co-developed with Alligator Bioscience targeting solid tumors.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing clinical development on lead candidate mipletamig, currently being evaluated in the RAINIER Phase 1b/2 trial in combination with venetoclax and azacitidine for frontline AML patients unfit for intensive chemotherapy.
Expected impact: Establish a highly differentiated safety and efficacy profile (81% remission rate demonstrated through Cohort 5) compared to standard-of-care benchmarks.
Expanding the company's CD3-engaging portfolio to five molecules, including the introduction of its first two trispecific candidates (APVO451 targeting Nectin-4/CD3/CD40 and APVO452 targeting PSMA/CD3/CD40) for solid tumors.
Expected impact: Broaden the therapeutic reach of the proprietary ADAPTIR and ADAPTIR-FLEX platforms into solid tumor indications.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Expands Aptevo's pipeline into radiopharmaceutical therapeutics by pairing Aptevo's multispecific antibody targeting assets (beginning with Nectin-4 targeting molecules like APVO455) with Niowave's radioisotope production capabilities (including Actinium-225).
Terms: Structured as a 50/50 collaboration to develop up to three radiopharmaceutical programs. At closing, Niowave made a $500,000 at-the-market equity investment in Aptevo, acquiring an initial 7.9% ownership stake with the potential to reach up to 19.99% through warrant exercises.
Joint development of ALG.APV-527, a bispecific conditional 4-1BB agonist targeting the 5T4 tumor antigen, designed to treat multiple solid tumor types.
Terms: The parties jointly own the candidate and share equally (50/50) all development costs associated with advancing ALG.APV-527 through the end of Phase 2 clinical development.